Factors associated with the development of cytomegalovirus infection following solid organ transplantation

Scandinavian Journal of Infectious Diseases

Volumn 43, Issue 5, 2011, Pages 360-365

  Da Cunha Bang, Caspar ^a,b   Sørensen, Søren S ^b   Iversen, Martin ^b   Sengeløv, Henrik ^b   Hillingsø, Jens G ^a   Rasmussen, Allan ^a   Mortensen, Svend A ^b   Fox, Zoe V ^a,c   Kirkby, Nikolai S ^a   Christiansen, Claus B ^a   Lundgren, Jens D ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

CMV infection; serostatus; transplantation

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CHILD; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; ORGAN TRANSPLANTATION; RISK FACTOR; SCHOOL CHILD; VIRUS DETECTION;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CHILD; COHORT STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DENMARK; FEMALE; FOLLOW-UP STUDIES; GANCICLOVIR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; RETROSPECTIVE STUDIES; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; TISSUE DONORS; YOUNG ADULT;

EID: 79954489163     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2010.549836     Document Type: Article

References (19)

1. Hodson EM, Jones CA, Webster AC, Strippoli GF, Barclay PG, Kable K, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005;365:2105-15. (Pubitemid 40826968)
2. Fishman JA, Emery V, Freeman R, Pascual M, Rostaing L, Schlitt HJ, et al. Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant 2007;21:149-58. (Pubitemid 46505720)
3. Hodson EM, Craig JC, Strippoli GF, Webster AC. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2008;(2):CD003774.
4. Strippoli GF, Hodson EM, Jones CJ, Craig JC. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2006;(1):CD005133.
5. Ljungman P, De La Camara R, Cordonnier C, Einsele H, Engelhard D, Reusser P, et al. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant 2008;42:227-40.
6. Styczynski J, Reusser P, Einsele H, de la Cámara R, Cordonnier C, Ward KN, et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009; 43:757-70.
7. Cope AV, Sabin C, Burroughs A, Rolles K, Griffiths PD, Emery VC. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor - recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J Infect Dis 1997;176:1484-90. (Pubitemid 27518147)
8. Helantera I, Koskinen P, Finne P, Loginov R, Kyllonen L, Salmela K, et al. Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survival. Transpl Int 2006;19:893-900. (Pubitemid 44511113)
9. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007;357:2601-14. (Pubitemid 350294226)
10. Funk GA, Gosert R, Hirsch HH. Viral dynamics in transplant patients: implications for disease. Lancet Infect Dis 2007;7:460-72. (Pubitemid 46962344)
11. DiDomenico N, Link H, Knobel R, Caratsch T, Weschler W, Loewy ZG, et al. COBAS AMPLICOR: fully automated RNA and DNA amplification and detection system for routine diagnostic PCR. Clin Chem 1996;42:1915-23. (Pubitemid 26415339)
12. Rossini F, Terruzzi E, Cammarota S, Morini F, Fumagalli M, Verga L, et al. Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program. Transpl Infect Dis 2005;7:122-5. (Pubitemid 43015447)
13. Husain S, Pietrangeli CE, Zeevi A. Delayed onset CMV disease in solid organ transplant recipients. Transpl Immunol 2009;21:1-9.
14. Balthesen M, Messerle M, Reddehase MJ. Lungs are a major organ site of cytomegalovirus latency and recurrence. J Virol 1993;67:5360-6. (Pubitemid 23241369)
15. Burton CM, Kristensen P, Lutzhoft R, Rasmussen M, Milman N, Carlsen J, et al. Cytomegalovirus infection in lung transplant patients: the role of prophylaxis and recipient - donor serotype matching. Scand J Infect Dis 2006; 38:281-9.
16. Grundy JE, Lui SF, Super M, Berry NJ, Sweny P, Fernando ON, et al. Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus. Lancet 1988;2:132-5.
17. Hughes D, Hafferty J, Fulton L, Friend P, Devaney A, Loke J, et al. Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patients. J Clin Virol 2008;41:92-5. (Pubitemid 351179453)
18. Arthurs SK, Eid AJ, Pedersen RA, Kremers WK, Cosio FG, Patel R, et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008;46:840-6. (Pubitemid 351417184)
19. Helantera I, Lautenschlager I, Koskinen P. Prospective followup of primary CMV infections after 6 months of valganciclovir prophylaxis in renal transplant recipients. Nephrol Dial Transplant 2009;24:316-20.